Serous borderline ovarian tumors: Where are we now?

In the present article we report the revised microscopical features of serous borderline ovarian tumors (S-BOTs) in the context of a long personal experience, drawing parallels with the definitions and issues elaborated at the Borderline Ovarian Tumor Workshop held in August 2003 in Bethesda. In our opinion none of the histopathologic criteria of the primary tumor including micropapillary subtype of the S-BOT can be used yet as a prognostic marker. The most realistic assumption is that in the clinical course of the S-BOT dynamic transformation of different clones occurs and the process develops simultaneously with multicentric blastomogenesis in the peritoneal cavity. Hence the failure of our efforts to forecast the prognosis of the disease using the microscopical structure of the primary tumor as a point of issue. It is indispensable to control the course of the S-BOTs by performing repeated biopsies at each relapse and modify the treatment schedules according to the microscopic patterns revealed at a given stage of the disease. Relapses of the S-BOTS may occur up to 50 years later so the patient should be under surveillance especially by a urologist to detect the earliest symptoms of urinary tract obstruction. Much more attention should be paid to the local intraabdominal administration of drugs and the search for new systemic chemotherapy regimens.

Serous borderline ovarian tumors; Borderline ovarian tumors; Ovanan cancer

[1] Silva E.G., Kurman R.J., Russel P., Scully R.E.: "Symposium: Ovarian tumors of borderline malignancy". Intern. J. Gynecol. Pathology, 1996, 15, 4, 281.

[2] Silverberg S.G., Bell D.A., Kunnan R.J. et al.: "Borderline ovarian tumors: Key points and workshop summary". Hum. Pathol., 2004, 35, 910.

[3] Seidman J.D., Soslow R.A., Vang R. et al.: "Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images". Hum. Pathol., 2004, 35, 918.

[4] Bell D.A., Longacre T.A., Prat J. et al.: "Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: Workshop perspectives". Hum. Pathol., 2004, 35, 934.

[5] Sherman M.E., Berman J., Birrer M.J. et al.: "Current challenges and opportunities for research on borderline ovarian tumors". Hum. Pathol., 2004, 35, 961.

[6] Russel P.: "Ovarian epithelial tumours with atypical proliferation". In: Lowe D., Fox H. (eds.). Advances in Gynaecologic Pathology. Edmburgh: Churchill Livingstone 1992, 299.

[7] Kurman R.J., Trimble C.L.: "The behavior of serous tumors of low malignant potential: are they ever malignant?". Int. J. Gynecol. Pathol., 1993, 12, 120.

[8] Scully R.E.: "Histological typing of ovarian tumours (WHO: International Histological Classification of Tumours)". 1999, Berlin and He1-delberg, Springer Verlag.

[9] Serov S.F., Scully R.E., Sobin L.H.: "Histologic typing of ovarian tumours". In: "International Histological Classification of Tumours". 1973, 9.

[10] Bell D.A., Weinstock M.A., Scully R.E.: "Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis". Cancer, 1988, 62, 2212.

[11] Kennedy A.W., Hart W.R.: "Ovarian papillary serous tumors of low malignant potencial (serous borderline tumors)". Cancer, 1996, 78, 278.

[12] Segal G.H., Hart W.R.: "Ovarian serous tumors of low malignant potential (serous borderline tumors): the relationship of exophytic surface tumor to peritoneal implants". Am. J. Surg. Pathol., 1992, 16, 577.

[13] Burks R.T., Sherman H.E., Kurman R.J.: "Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors". Am. J. Surg. Pathol., 1996, 20, 11, 1319.

[14] Tavassoli F.A.: "Serous tumors of low malignant potential with early stromal invasion (serous LMP with microinvasion)". Mod. Pathol., 1988, 1, 407.

[15] Bell D.A., Scully R.E.: "Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases". Hum. Pathol., 1990, 21, 397.

[16] Bell D.A., Scully R.E.: "Benign and borderline serous tumors of the peritoneum in women". Pathol. Annu., 1989, 242, 1.

[17] Gu J., Roth L.M., Younger C. et al.: "Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential". J. Natl. Cancer Inst., 2001, 93, 1147.

[18] Sieben N.L.G., Kolkman-Uljle, Flnagan A.M. et al.: "Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors". Am. J. Pathol., 2003, 162, 1095.

[19] Barakat R.R., Benjamin I., Lewis J.L. et al.: "Platinum based chemotherapy for advanced-stage ovarian carcinoma of low malignant potential". Gynecol. Oncol., 1995, 59, 390.